// App-Quantinova.ai

: Reprogramming Macrophages Using Autologous Hematopoietic Stem Cells As Immunotherapy for Glioblastoma: TEM-GBM Study (NCT03866109)

Researchers

Presenter

  • Francesca Farina

Principal Investigators

  • Gaetano Finocchiaro

  • Marica Eoli

  • Alessia Capotondo

  • Elena Anghileri

  • Matteo Barcella

  • Valentina Brambilla

  • Maria Grazie Bruzzone

  • Matteo Giovanni Carrabba

  • Valeria Cuccarini

  • Giorgio D'Alessandris

  • Francesco DI Meco

  • Valeria Ferla

  • Alberto Franzin

  • Paolo Ferroli

  • Filippo Gagliardi

  • Federico Legnani

  • Stefania Mazzoleni

  • Pietro Mortini

  • Matteo Maria Naldini

  • Alessandro Olivi

  • Roberto Pallini

  • Monica Patane

  • Rosina Paterra

  • Bianca Pollo

  • Marco Saini

  • Silvia Snider

  • Andrew Zambanini

  • Luigi Naldini

  • Carlo Russo

  • Fabio Ciceri

Medical Centers

  • Hematology and Bone Marrow Transplantation Unit, IRCCS San Raffaele Hospital, Milano, Italy

  • Neurosurgery Unit, Fondazione Poliambulanza, Brescia, Italy

  • San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), San Raffaele Scientific Institute, Milano, Italy

  • Neurosurgery Unit, Policlinico Gemelli, Rome, Italy

  • Neurosurgery Unit, IRCCS San Raffaele Hospital, Milano, Italy

  • Neuro-Oncology Unit, IRCCS Istituto Neurologico Carlo Besta, Milano, Italy

  • Genenta Science, New York

  • Genenta Science, Milano, Italy

Locations

  • Italy

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Glioblastoma

Biomarkers

  • O-6-methylguanine DNA methyltransferase

  • Cluster of Differentiation 34

Drug/Treatment

  • lenograstim

  • Plerixafor

  • Hydroxyzine

  • Busulfan

  • Thiotepa

  • IFN-lambda

Outcome

  • N/A

Study Design

  • Efficacy

  • Safety

  • Fixed Dose

  • Open Label

  • Dose Escalation

Phase

  • I/II

Study Id's

  • NCT03866109

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved